APO866 activity in hematologic malignancies: a preclinical in vitro study
- PMID: 19498032
- DOI: 10.1182/blood-2009-03-209213
APO866 activity in hematologic malignancies: a preclinical in vitro study
Comment on
-
The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.Blood. 2009 Apr 2;113(14):3276-86. doi: 10.1182/blood-2008-08-173369. Epub 2009 Feb 5. Blood. 2009. PMID: 19196867
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources

